RemeGen Co., Ltd. (HKG:9995)
79.35
-1.35 (-1.67%)
Sep 1, 2026, 4:08 PM HKT
RemeGen Revenue
RemeGen had revenue of 5.20B CNY in the quarter ending June 30, 2026, with 808.60% growth. This brings the company's revenue in the last twelve months to 8.01B, up 286.21% year-over-year. In the year 2025, RemeGen had annual revenue of 3.25B with 89.36% growth.
Revenue (ttm)
8.01B CNY
Revenue Growth
+286.21%
P/S Ratio
7.12
Revenue / Employee
2.55M CNY
Employees
3,145
Market Cap
65.83B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.25B | 1.53B | 89.36% |
| Dec 31, 2024 | 1.72B | 633.91M | 58.54% |
| Dec 31, 2023 | 1.08B | 310.84M | 40.26% |
| Dec 31, 2022 | 772.11M | -651.79M | -45.78% |
| Dec 31, 2021 | 1.42B | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sino Biopharmaceutical | 38.91B |
| 3SBio | 20.63B |
| Innovent Biologics | 18.13B |
| Shanghai Henlius Biotech | 8.58B |
| Genscript Biotech | 6.63B |
| Akeso | 3.98B |
| Shanghai Junshi Biosciences | 3.49B |
| InnoCare Pharma | 3.21B |
RemeGen News
- 8 days ago - RemeGen Earnings release: Q2 2026 - Filings
- 4 months ago - RemeGen Earnings release: Q1 2026 - Filings
- 5 months ago - RemeGen Annual report: Q4 2025 - Filings
- 5 months ago - RemeGen Slides: Q4 2025 - Filings
- 5 months ago - RemeGen Earnings release: Q4 2025 - Filings
- 8 months ago - AbbVie, RemeGen partner on experimental solid tumor treatment - Reuters
- 10 months ago - RemeGen Earnings release: Q3 2025 - Filings
- 10 months ago - RemeGen Slides: Q3 2025 - Filings